Repligen (NASDAQ: RGEN) — Perfil da empresa, notícias e dados financeiros
Repligen develops bioprocessing technologies for the biopharmaceutical industry, enhancing manufacturing efficiency and product quality.
Repligen
Repligen is a global life sciences company that develops and manufactures bioprocessing technologies and systems used in the process development and commercial manufacturing of biological drugs. Its product portfolio spans upstream filtration, downstream filtration, chromatography, process analytics, single-use fluid management, cell culture supplements, and dialysis. The company serves biopharmaceutical and biotechnology companies, as well as contract development and manufacturing organizations, supporting production across monoclonal antibodies, gene therapies, cell therapies, vaccines, and recombinant proteins. Repligen operates manufacturing facilities and commercial offices globally, delivering hardware, consumables, and analytical software designed to optimize yield and scale biopharmaceutical production processes.
Resumo
Operações
Produtos e/ou serviços de Repligen
- Upstream Filtration: Perfusion systems, alternating tangential flow devices, and thin-film tangential flow filtration hardware deployed in bioreactors to achieve higher cell culture densities, continuous media exchange, and enhanced space-time yields during upstream cell culture processes.
- Downstream Filtration: Tangential flow filtration systems, single-use cassettes, and hollow fiber filter modules engineered for concentration and diafiltration steps, enabling reliable buffer exchange, high product recovery, and clarification across biopharmaceutical purification operations.
- Chromatography Solutions: Pre-packed chromatography columns ranging from laboratory scale to large commercial GMP sizes, paired with recombinant Protein A affinity resins and ion exchange resins used for mAb and viral vector purification.
- Process Analytics: Slanted-path length slope spectroscopy instruments, online glucose and lactate analyzers, microfluidic interfaces, and real-time process analytics software used for slope-based protein concentration measurement, nutrient tracking, and inline critical parameter monitoring.
- Single-Use Fluid Management: Standardized and custom single-use bioprocess bags, flow path assemblies, molded connectors, specialized single-use valves, and automated magnetic mixing systems designed for hygienic transfer, storage, and mixing of fluids in biomanufacturing.
- Cell Culture Supplements and Dialysis: Recombinant human growth factor supplements used to enhance cell proliferation in serum-free cell culture media, together with specialized cellulose membranes, dialysis tubing, and ready-to-use devices for molecular purification.
equipe executiva do Repligen
- Olivier LoeillotPresident, CEO & Director
- Jason K. GarlandCFO & Chief Compliance Officer
- James R. BylundChief Operating Officer
- Anthony J. HuntAdvisor
- Ralf KuriyelSenior Vice President of Research & Development
- Brian DouglassSenior VP & Chief Product Officer
- Violetta HughesChief Accounting Officer
- Heather EmsChief Information Officer
- Jacob K. JohnsonVice President of Investor Relations
- George A Scott Jr.Senior VP & General Counsel
Últimas notícias sobre a Repligen
Principais indicadores financeiros
Resultados divulgados pela Repligen , em USD.
- Cap. de mercado
- 11,7 bi
- Receita (TTM)
- 805,6 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.2
- Dividend yield
- —
- Margem de lucro
- -1.5%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 738,3 mi | 59,6 mi | 48,9 mi | |
| 634,4 mi | -35,1 mi | -25,5 mi | |
| 638,8 mi | 54,6 mi | 41,6 mi | |
| 801,5 mi | 224,7 mi | 186 mi |